There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Omega Therapeutics (OMGA – Research Report), Esperion (ESPR – Research Report) and Aeterna Zentaris (AEZS – Research Report) with bullish sentiments.
Omega Therapeutics (OMGA)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Omega Therapeutics today and set a price target of $12.00. The company’s shares closed last Friday at $1.72, close to its 52-week low of $1.30.
According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omega Therapeutics with a $12.20 average price target, a 634.9% upside from current levels. In a report issued on November 1, Piper Sandler also initiated coverage with a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Esperion (ESPR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Esperion, with a price target of $22.00. The company’s shares closed last Friday at $0.91, close to its 52-week low of $0.70.
According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Esperion is a Strong Buy with an average price target of $11.80, implying an 1196.7% upside from current levels. In a report issued on November 7, TD Cowen also maintained a Buy rating on the stock with a $6.00 price target.
Aeterna Zentaris (AEZS)
H.C. Wainwright analyst Boobalan Pachaiyappan reiterated a Buy rating on Aeterna Zentaris today and set a price target of $15.00. The company’s shares closed last Friday at $1.45, close to its 52-week low of $1.36.
According to TipRanks.com, Pachaiyappan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Aeterna Zentaris is a Moderate Buy with an average price target of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OMGA:
- Omega Therapeutics price target lowered to $12 from $19 at Wedbush
- Omega Therapeutics reports Q3 EPS (40c), consensus (53c)
- Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Omega presents new preclinical data on pre-transcriptional control of genes
- Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
